|ORGS -- USA Stock|| |
USD 9.01 0.21 2.28%
Chief Scientific Officer
Prof. Sarah Ferber, Ph.D., is Chief Scientific Officer of Orgenesis Inc. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a postdoctoral fellowship at the Joslin Diabetes Lab at Harvard Medical School. Prof. Ferbers breakthrough discovery suggested that humans carry their own stemcells throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferbers lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferbers research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.
Age: 59 Executive Since 2012
Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.
The company has return on total asset (ROA)
of (16.08) %
which means that it has lost $16.08 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (80.6) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.53 M in liabilities with Debt to Equity (D/E) ratio of 19.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orgenesis has Current Ratio of 0.52 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in USA and traded on OTC Market. It employs 103 people.Orgenesis (ORGS) is traded on OTC Market in USA. It is located in MARYLAND, U.S.A and employs 103 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.
Orgenesis Leadership Team
|David Sidransky, Director|
|Yaron Adler, Director|
|Marie Bouillez, Director|
|Neil Reithinger, CFO|
|Scott Carmer, CEO|
|Etti Hanochi, Director, MBA|
|Hugues Bultot, Director|
|Guy Yachin, Director, MBA|
|Chris Buyse, Director|
|Vered Caplan, Chairman|
|Sarah Ferber, Executive|
Stock Performance Indicators
Most of Macroaxis users are now bullish on Orgenesis. What is your perspective on investing in Orgenesis? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally take a look at Your Equity Center
. Please also try Fund Screener
module to find activelly-traded funds from around the world traded on over 30 global exchanges.